HIV/AIDS
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Published in Proteomics Weekly, March 12th, 2007
Virtually all patients (98 percent) who received the investigational integrase inhibitor raltegravir, along with FUZEON(R) (enfuvirtide) and an active boosted protease inhibitor (darunavir), achieved undetectable levels of HIV (less than 400 copies/mL of blood), according to new interim 16-week clinical data presented this week at the 14th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Los Angeles. Such a high response rate has never been seen in patients who have developed resistance to at least one agent in each of the first three classes of antiretrovirals.
FUZEON, co-developed by Roche and Trimeris (Nasdaq: TRMS), is the first and only...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
Source: Proteomics Weekly (2007-03-12)
More Articles from Proteomics Weekly
- Financing
Geron Corporation Announces Exercise of Warrants for $15.0 Million of Proceeds - HIV/AIDS
Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137 - HIV/AIDS
Gilead Announces Completion of Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137 - HIV/AIDS
Surveyed HIV Specialists Say That a Novel Integrase Inhibitor Could Potentially Capture More Than 20% of the HIV Market - Meningitis
454 Sequencing Reveals Novel Aspects of a Human Pathogen - Patents
Vaxiion Therapeutics, Inc. Granted Broad Patent Protection for Breakthrough Vaccine Delivery System - More from this issue of Proteomics Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
